Skip to main content

KMT2A-rearranged

1
Pipeline Programs
2
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
2100%

Competitive Landscape

2 companies ranked by most advanced pipeline stage

General Oncology
General OncologyMA - Brookline
1 program
1
ZiftomenibPhase 1Small Molecule1 trial
Active Trials
NCT07355335Not Yet Recruiting24Est. Jan 2028
Kura Oncology
Kura OncologySAN DIEGO, CA
1 program
ZiftomenibPHASE_1Small Molecule

Trial Timeline

Clinical trial activity over time

2026
2027
2028
General OncologyZiftomenib

Clinical Trials (1)

Total enrollment: 24 patients across 1 trials

Ziftomenib + Mezigdomide in Adolesc. and Adults w/ R/R AML

Start: Jul 2026Est. completion: Jan 202824 patients
Phase 1Not Yet Recruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.